We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Priority Review to Biogen’s Tofersen for Rare Form of ALS
FDA Gives Priority Review to Biogen’s Tofersen for Rare Form of ALS
The FDA has granted priority review status to Biogen’s New Drug Application for tofersen, giving the drugmaker an early win in its battle for an amyotrophic lateral sclerosis (ALS) therapy.